Clinical development of immunotherapy for prostate cancer
Prostate cancer is the most common cancer in men, and the second leading cause of cancer‐related death in Western countries. Prostate cancer‐related death occurs in patients with metastatic castration‐resistant prostate cancer. Although several new drugs for castration‐resistant prostate cancer have...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2017-09, Vol.24 (9), p.675-680 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 680 |
|---|---|
| container_issue | 9 |
| container_start_page | 675 |
| container_title | International journal of urology |
| container_volume | 24 |
| creator | Noguchi, Masanori Koga, Noriko Igawa, Tsukasa Itoh, Kyogo |
| description | Prostate cancer is the most common cancer in men, and the second leading cause of cancer‐related death in Western countries. Prostate cancer‐related death occurs in patients with metastatic castration‐resistant prostate cancer. Although several new drugs for castration‐resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed. |
| doi_str_mv | 10.1111/iju.13397 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1912192328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1937897549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4127-791cdd093c105a0d1c485c18a03d90527cef29d5008778c51f03f6df771884873</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgiq3VhS8gA250MW1OkmmSpRQvlYIbuw4xF5wyl5rMKH17o1NdCGZzNh__OfkROgc8hfRm5aafAqWSH6AxMEZyghk5RGMsQeYCOBmhkxg3GAMlII7RiIg5nQMjYyQXVdmURleZde-uare1a7qs9VlZ133Tdq8u6O0u823ItqGNne5cZnRjXDhFR15X0Z3t5wSt726fFw_56ul-ubhZ5YYB4TmXYKzFkhrAhcYWDBOFAaExtRIXhBvnibQFxoJzYQrwmPq59ZyDEExwOkFXQ27a_9a72Km6jMZVlW5c20cFEghIQolI9PIP3bR9aNJ1SVEuJC-YTOp6UCZ9KAbn1TaUtQ47BVh99alSn-q7z2Qv9on9S-3sr_wpMIHZAD7Kyu3-T1LLx_UQ-QmPmnza</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937897549</pqid></control><display><type>article</type><title>Clinical development of immunotherapy for prostate cancer</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Noguchi, Masanori ; Koga, Noriko ; Igawa, Tsukasa ; Itoh, Kyogo</creator><creatorcontrib>Noguchi, Masanori ; Koga, Noriko ; Igawa, Tsukasa ; Itoh, Kyogo</creatorcontrib><description>Prostate cancer is the most common cancer in men, and the second leading cause of cancer‐related death in Western countries. Prostate cancer‐related death occurs in patients with metastatic castration‐resistant prostate cancer. Although several new drugs for castration‐resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.13397</identifier><identifier>PMID: 28636142</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>cancer vaccine ; Cancer vaccines ; Castration ; chimeric antigen receptor T cells ; Immune checkpoint inhibitors ; Immunosuppressive agents ; Immunotherapy ; Metastases ; Prostate cancer ; Studies ; tumor microenvironment</subject><ispartof>International journal of urology, 2017-09, Vol.24 (9), p.675-680</ispartof><rights>2017 The Japanese Urological Association</rights><rights>2017 The Japanese Urological Association.</rights><rights>Copyright © 2017 The Japanese Urological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4127-791cdd093c105a0d1c485c18a03d90527cef29d5008778c51f03f6df771884873</citedby><cites>FETCH-LOGICAL-c4127-791cdd093c105a0d1c485c18a03d90527cef29d5008778c51f03f6df771884873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fiju.13397$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fiju.13397$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28636142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noguchi, Masanori</creatorcontrib><creatorcontrib>Koga, Noriko</creatorcontrib><creatorcontrib>Igawa, Tsukasa</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><title>Clinical development of immunotherapy for prostate cancer</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Prostate cancer is the most common cancer in men, and the second leading cause of cancer‐related death in Western countries. Prostate cancer‐related death occurs in patients with metastatic castration‐resistant prostate cancer. Although several new drugs for castration‐resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed.</description><subject>cancer vaccine</subject><subject>Cancer vaccines</subject><subject>Castration</subject><subject>chimeric antigen receptor T cells</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Metastases</subject><subject>Prostate cancer</subject><subject>Studies</subject><subject>tumor microenvironment</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10MtKAzEUBuAgiq3VhS8gA250MW1OkmmSpRQvlYIbuw4xF5wyl5rMKH17o1NdCGZzNh__OfkROgc8hfRm5aafAqWSH6AxMEZyghk5RGMsQeYCOBmhkxg3GAMlII7RiIg5nQMjYyQXVdmURleZde-uare1a7qs9VlZ133Tdq8u6O0u823ItqGNne5cZnRjXDhFR15X0Z3t5wSt726fFw_56ul-ubhZ5YYB4TmXYKzFkhrAhcYWDBOFAaExtRIXhBvnibQFxoJzYQrwmPq59ZyDEExwOkFXQ27a_9a72Km6jMZVlW5c20cFEghIQolI9PIP3bR9aNJ1SVEuJC-YTOp6UCZ9KAbn1TaUtQ47BVh99alSn-q7z2Qv9on9S-3sr_wpMIHZAD7Kyu3-T1LLx_UQ-QmPmnza</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Noguchi, Masanori</creator><creator>Koga, Noriko</creator><creator>Igawa, Tsukasa</creator><creator>Itoh, Kyogo</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201709</creationdate><title>Clinical development of immunotherapy for prostate cancer</title><author>Noguchi, Masanori ; Koga, Noriko ; Igawa, Tsukasa ; Itoh, Kyogo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4127-791cdd093c105a0d1c485c18a03d90527cef29d5008778c51f03f6df771884873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>cancer vaccine</topic><topic>Cancer vaccines</topic><topic>Castration</topic><topic>chimeric antigen receptor T cells</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Metastases</topic><topic>Prostate cancer</topic><topic>Studies</topic><topic>tumor microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noguchi, Masanori</creatorcontrib><creatorcontrib>Koga, Noriko</creatorcontrib><creatorcontrib>Igawa, Tsukasa</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noguchi, Masanori</au><au>Koga, Noriko</au><au>Igawa, Tsukasa</au><au>Itoh, Kyogo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical development of immunotherapy for prostate cancer</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2017-09</date><risdate>2017</risdate><volume>24</volume><issue>9</issue><spage>675</spage><epage>680</epage><pages>675-680</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Prostate cancer is the most common cancer in men, and the second leading cause of cancer‐related death in Western countries. Prostate cancer‐related death occurs in patients with metastatic castration‐resistant prostate cancer. Although several new drugs for castration‐resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28636142</pmid><doi>10.1111/iju.13397</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2017-09, Vol.24 (9), p.675-680 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1912192328 |
| source | Wiley Online Library - AutoHoldings Journals |
| subjects | cancer vaccine Cancer vaccines Castration chimeric antigen receptor T cells Immune checkpoint inhibitors Immunosuppressive agents Immunotherapy Metastases Prostate cancer Studies tumor microenvironment |
| title | Clinical development of immunotherapy for prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20development%20of%20immunotherapy%20for%20prostate%20cancer&rft.jtitle=International%20journal%20of%20urology&rft.au=Noguchi,%20Masanori&rft.date=2017-09&rft.volume=24&rft.issue=9&rft.spage=675&rft.epage=680&rft.pages=675-680&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.13397&rft_dat=%3Cproquest_cross%3E1937897549%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1937897549&rft_id=info:pmid/28636142&rfr_iscdi=true |